Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solbinsiran - Eli Lilly and Company

Next Previous
Search
Drug Profile

Solbinsiran - Eli Lilly and Company

Alternative Names: ANGPTL3-siRNA - Eli Lilly and Company; DCR-CM1; LY-3561774

Latest Information Update: 06 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Developer Dicerna Pharmaceuticals; Eli Lilly and Company
  • Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cardiovascular disorders; Dyslipidaemias
  • No development reported Metabolic disorders

Most Recent Events

  • 23 May 2024 Eli Lilly and Company completes a phase-II clinical trial in Dyslipidaemias in Turkey, Poland, Japan, Canada, Argentina, Argentina, USA and Mexico (SC) (NCT05256654)
  • 28 Apr 2024 No recent reports of development identified for phase-I development in Metabolic-disorders in USA (SC)
  • 06 Apr 2024 Adverse events and pharmacodynamics data from a phase I trial in dyslipidaemias presented at the 73rd Annual Scientific Session of the American College of Cardiology (ACC-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top